



**MEDIA RELEASE –FOR IMMEDIATE RELEASE**

**Immunotec mourns passing of Senior VP - Dr. Wulf Dröge, Ph.D.**

VAUDREUIL-DORION, QC, December 22, 2010 - It is with deep sadness that Immunotec Inc. announces the death of its colleague, leader and friend, Dr. Wulf Dröge, Senior Vice-President, Research & Development.

Dr. Dröge, was a world-renowned scientist with more than forty years in basic and clinical research and participation in more than 280 publications, in the areas of redox modulation and aging. After completing a postdoctoral fellowship at the Max Planck Institute and at Harvard University, Dr. Dröge spent 3 years as a scientific member at the renowned Basel Institute of Immunology and 29 years as professor of cell biology at the University of Heidelberg as well as department head at the National Cancer Research Center of Germany (Deutsches Krebsforschungszentrum).

After his retirement from the academic sector, he joined Immunotec in 2005 as head of Research and Development, and he contributed greatly to promoting the benefits of cysteine supplementation with Immunocal®. He was the architect of the Immunocal® Platinum product, one of the Company's flagship products.

"We wish to express our most sincere condolences to his wife and to their daughter", said James A. Northrop, President and CEO of Immunotec Inc. "The scientific community has lost a great leader and Immunotec owes Wulf a tremendous debt of gratitude for his contributions over the years".

*About Immunotec Inc.*

Immunotec is a Network Marketing Company involved in the direct selling of scientifically validated natural health products and dietary supplements. The Company offers a lucrative business opportunity to its independent distributors. This business model provides Immunotec's network of people with an opportunity to earn a steady and recurring income, directly based on their level of involvement and performance. Individual distributors build their business by conveying product information and selling product to customers and by building teams of distributors to expand geographic penetration and market coverage to larger populations of customers.

Headquartered with manufacturing facilities near Montreal, Canada, the Company also subcontracts certain distribution logistics and capacity to support its activities in the United States, Europe, Mexico and The Caribbean.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at [www.sedar.com](http://www.sedar.com) and on the Company's website at [www.immunotec.com](http://www.immunotec.com). The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

"The TSX Venture does not accept responsibility for the adequacy or accuracy of this release."

**For further information:** Patrick Montpetit, VP and Chief Financial Officer, (450) 510-4527.